The company received notification from French pharmaceutical regulatory agency l’Agence National de Sécurité du Médicament et des produits de santé (ANSM) to suspend manufacturing within the site. Catalent
Sparsentan, also known as RE-021, is an investigational therapeutic agent which acts as a potent angiotensin receptor blocker, and a selective endothelin receptor antagonist, with in vitro selectivity
Binimetinib and encorafenib are currently in phase 3 trials to treat melanoma and ovarian cancer. Array will receive an upfront payment of $30m and retain exclusive commercialization rights
Under the collaboration, Emerson’s DeltaV distributed control system will be integrated with GE’s technologies to manufacture monoclonal antibodies, vaccines and other biologics. The initial DeltaV-driven GE Healthcare installation
Darzalex is a monoclonal antibody that is designed to help the body’s immune system fight cancer cells. In clinical studies involving over 140 people, Darzalex reduced the cancer’s
Mylan offered $75 in cash and 2.3 ordinary shares for each Perrigo share. Perrigo has however called the Mylan proposal inadequate. Following the offer expiry, Mylan executive chairman
The Phase III trial assessed Imbruvica plus bendamustine and rituximab (BR) versus placebo plus BR in relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The results
The nexgen-PTS expands the company’s microbial solutions offering within its microbiology portfolio, which features microbial detection, bioburden testing and microbial identification. The Endosafe nexgen-PTS features touch screen display,
Xadago, which is being developed by Zambon and its partner Newron Pharmaceuticals, was approved as add-on therapy to levodopa (L-dopa) alone or in combination with other PD therapies
Tagrisso is indicated to treat patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). In two clinical trials of 411 subjects, 57%
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.